Simulations Plus (NASDAQ:SLP) shares hit a new 52-week high and low during mid-day trading on Monday . The company traded as low as $18.55 and last traded at $18.35, with a volume of 49668 shares changing hands. The stock had previously closed at $18.20.
SLP has been the topic of a number of analyst reports. Zacks Investment Research upgraded Simulations Plus from a “sell” rating to a “hold” rating in a report on Wednesday, January 24th. BidaskClub cut Simulations Plus from a “hold” rating to a “sell” rating in a research report on Friday, January 26th. Finally, ValuEngine raised Simulations Plus from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd.
Get Simulations Plus alerts:
The stock has a market capitalization of $315.33 million, a price-to-earnings ratio of 54.41 and a beta of -0.56.
Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings data on Monday, April 9th. The technology company reported $0.11 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.11. The firm had revenue of $7.36 million during the quarter, compared to analysts’ expectations of $7.37 million. Simulations Plus had a return on equity of 26.19% and a net margin of 30.65%. sell-side analysts predict that Simulations Plus will post 0.4 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 2nd. Stockholders of record on Wednesday, April 25th were given a $0.06 dividend. The ex-dividend date of this dividend was Tuesday, April 24th. This represents a $0.24 dividend on an annualized basis and a dividend yield of 1.30%. Simulations Plus’s payout ratio is 70.59%.
In other Simulations Plus news, Chairman Walter S. Woltosz sold 18,500 shares of Simulations Plus stock in a transaction dated Tuesday, March 27th. The stock was sold at an average price of $14.54, for a total transaction of $268,990.00. Following the completion of the sale, the chairman now owns 5,466,408 shares of the company’s stock, valued at approximately $79,481,572.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO John Robert Kneisel sold 2,991 shares of Simulations Plus stock in a transaction dated Friday, April 20th. The stock was sold at an average price of $17.64, for a total value of $52,761.24. The disclosure for this sale can be found here. Insiders sold a total of 58,491 shares of company stock valued at $938,356 in the last three months. Insiders own 33.45% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the business. Bank of Montreal Can acquired a new stake in Simulations Plus during the 4th quarter worth about $104,000. The Manufacturers Life Insurance Company lifted its position in Simulations Plus by 142.2% during the 4th quarter. The Manufacturers Life Insurance Company now owns 9,378 shares of the technology company’s stock worth $151,000 after acquiring an additional 5,506 shares during the period. Strs Ohio lifted its position in Simulations Plus by 196.9% during the 4th quarter. Strs Ohio now owns 9,500 shares of the technology company’s stock worth $152,000 after acquiring an additional 6,300 shares during the period. Algert Global LLC acquired a new stake in Simulations Plus during the 4th quarter worth about $175,000. Finally, Wells Fargo & Company MN lifted its position in Simulations Plus by 234.1% during the 4th quarter. Wells Fargo & Company MN now owns 17,028 shares of the technology company’s stock worth $275,000 after acquiring an additional 11,931 shares during the period. 33.19% of the stock is owned by institutional investors.
About Simulations Plus
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.